Related Experiment Videos
Ribozyme-mediated trans-splicing of a trinucleotide repeat
L A Phylactou1, C Darrah, M J Wood
1Department of Human Anatomy, Oxford University, United Kingdom. leonidas.phylactou@anat.ox.ac.uk
Nature Genetics
|April 16, 1998
Summary
Trinucleotide repeat expansions (TREs) cause diseases like myotonic dystrophy (DM). Researchers developed a ribozyme to repair these expanded repeats, showing success in cellular models for a potential new genetic therapy.
Area of Science:
- Molecular Biology
- Genetics
- RNA Therapeutics
Background:
- Trinucleotide repeat expansions (TREs) are a class of mutations leading to genetic disorders such as Huntington disease and myotonic dystrophy (DM).
- Current genetic therapies for TRE-associated diseases have not yet achieved success.
- Group I intron ribozymes offer a potential therapeutic strategy for TREs through trans-splicing and repeat repair.
Purpose of the Study:
- To investigate the therapeutic potential of group I intron ribozymes for treating TRE-associated diseases, using DM as a model.
- To design and test a specific ribozyme (DMPK-RZ1) for modifying TREs in the human myotonic dystrophy protein kinase (DMPK) gene.
Main Methods:
- Designed a group I intron ribozyme (DMPK-RZ1) targeting the 3' end of DMPK transcripts.
- Evaluated the ribozyme's ability to ligate RNA fragments and modify target transcripts in vitro.
- Assessed the ribozyme's efficacy in mammalian cells, including its ability to modify endogenous DMPK mRNA.
Main Results:
- DMPK-RZ1 successfully ligated a DMPK mRNA fragment to a target RNA in vitro.
- The ribozyme modified a larger target transcript, reducing twelve repeats to five repeats, both in vitro and in mammalian cells.
- Endogenous DMPK mRNA in fibroblasts was modified by replacing its 3' region with a different sequence via the ribozyme.
Conclusions:
- Ribozyme-mediated RNA repair demonstrates a promising novel therapeutic strategy for diseases caused by repeat expansions.
- This approach shows potential for developing effective treatments for genetic disorders like myotonic dystrophy.